2-氨基甲基-1-甲基咪唑 | 124312-73-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-氨基甲基-1-甲基咪唑
• 中文别名: 1-甲基-2-咪唑甲胺
• 英文名称: (1-methyl-1H-imidazol-2-yl)methanamine
• 英文别名: C-(1-Methyl-1H-imidazol-2-yl)-methylamine；1-(1-methyl-1H-imidazol-2-yl)methanamine；(1-methylimidazol-2-yl)methanamine
• CAS: 124312-73-8
• 化学式: C₅H₉N₃
• mdl: MFCD06660876
• 分子量: 111.147
• InChiKey: PZSMLGOAJXSDMK-UHFFFAOYSA-N

物化性质

• 沸点：
  255.1±23.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• 海关编码：
  2933290090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319

SDS

Name:	(1-Methyl-1H-imidazol-2-yl)methylamine 97% Material Safety Data Sheet
Synonym:
CAS:	124312-73-8

Section 1 - Chemical Product MSDS Name:(1-Methyl-1H-imidazol-2-yl)methylamine 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
124312-73-8	(1-Methyl-1H-imidazol-2-yl)methylamine	97	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 124312-73-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid or liquid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H9N3
Molecular Weight: 111.15

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 124312-73-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(1-Methyl-1H-imidazol-2-yl)methylamine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.*
Hazard Class: 8
UN Number: 3259
Packing Group: III
IMO
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3259
Packing Group: III
RID/ADR
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3259
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 124312-73-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 124312-73-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 124312-73-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

沸点：255.1±23.0℃

反应信息

• 作为反应物：
  描述：

  2-氨基甲基-1-甲基咪唑 在 正丁基锂 、 仲丁基锂 作用下， 以 四氢呋喃 为溶剂， 生成 tert-butyl N-[N'-[(5-chlorosulfonyl-1-methylimidazol-2-yl)methyl]-N-[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]carbamate
  参考文献：
  名称：

  A novel synthetic approach towards 2-guanidinomethyl-4(5)-sulfamoylimidazoles

  摘要：

  A library of 2-guanidinomethyl-4(5)-sulfamoylimidazoles was synthesised in a convergent manner by introducing sulfonyl chloride group via a trianion electrophilic sulfinylation of suitably protected 2-guanidinomethyl imidazoles. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.05.143
• 作为产物：
  描述：

  1-甲基-1H-咪唑-2-甲醛 在 吡啶 、 盐酸羟胺 、 溶剂黄146 、 锌 作用下， 以 乙醇 为溶剂， 以90%的产率得到2-氨基甲基-1-甲基咪唑
  参考文献：
  名称：

  A novel synthetic approach towards 2-guanidinomethyl-4(5)-sulfamoylimidazoles

  摘要：

  A library of 2-guanidinomethyl-4(5)-sulfamoylimidazoles was synthesised in a convergent manner by introducing sulfonyl chloride group via a trianion electrophilic sulfinylation of suitably protected 2-guanidinomethyl imidazoles. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.05.143

文献信息

• Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents
  作者：Franck Amblard、Sebastien Boucle、Leda Bassit、Zhe Chen、Ozkan Sari、Bryan Cox、Kiran Verma、Tugba Ozturk、Olivia Ollinger-Russell、Raymond F. Schinazi

  DOI：10.1016/j.bmc.2020.115952

  日期：2021.2

  Chronic hepatitis B viral infection is a significant health problem world-wide, and currently available antiviral agents suppress HBV infections, but rarely cure this disease. It is presumed that antiviral agents that target the viral nuclear reservoir of transcriptionally active cccDNA may eliminate HBV infection. Through a series of chemical optimization, we identified a new series of glyoxamide

  慢性乙型肝炎病毒感染是世界范围内的一个重大健康问题，目前可用的抗病毒药物可以抑制 HBV 感染，但很少能治愈这种疾病。据推测，靶向转录活性 cccDNA 病毒核库的抗病毒药物可能会消除 HBV 感染。通过一系列化学优化，我们确定了一系列新的乙二酰胺衍生物，它们在低纳摩尔水平下影响 HBV 核衣壳形成和 cccDNA 维持。在合成的所有化合物中，GLP-26 显示出对 HBV DNA、HBeAg 分泌和 cccDNA 扩增的主要影响。此外，GLP-26 在人源化小鼠模型中显示出良好的临床前特征和对病毒载量的长期影响。
• [EN] NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES<br/>[FR] NOUVEAUX COMPOSÉS COMME STIMULANTS RESPIRATOIRES POUR LE TRAITEMENT DE TROUBLES OU DE MALADIES DE CONTRÔLE DE LA RESPIRATION
  申请人：GALLEON PHARMACEUTICALS INC

  公开号：WO2012074999A1

  公开（公告）日：2012-06-07

  The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention, The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.

  本发明涵盖了用于治疗患有呼吸控制疾病或紊乱的受试者的组合物。本发明还包括一种治疗患有呼吸系统疾病或紊乱的受试者的方法，包括向受试者施用本发明的药物配方的治疗有效量。本发明还包括一种预防或稳定患有呼吸节律不稳定的受试者的方法，包括向受试者施用本发明的药物配方的治疗有效量。
• NOVEL PYRAZINE AMIDE COMPOUNDS
  申请人：WIEDENMAYER Dieter

  公开号：US20150045326A1

  公开（公告）日：2015-02-12

  The present invention relates to compounds of formula 1 or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 5 , R 4 , R 5 , R 6 and X − have the meanings as indicated in the specification, to their use as a medicament, to their use in the treatment of a disease selected from among respiratory diseases or complaints and allergic diseases of the airways, to pharmaceutical composition comprising at least one of said compound or a pharmaceutically acceptable salt thereof, as well as to medicament combinations containing one or more of said compounds or a pharmaceutically acceptable salt thereof.

  本发明涉及式1的化合物或其药用盐，其中R1、R2、R3、R4、R5、R6和X-的含义如规范中所示，以及它们作为药物的用途，用于治疗呼吸道疾病或疾病和过敏性呼吸道疾病中选择的疾病，包括至少一种所述化合物或其药用盐的药物组合的制药组合。
• [EN] NOVEL PYRAZINE AMIDE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS PYRAZINE-AMIDES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2015018754A1

  公开（公告）日：2015-02-12

  The present invention relates to compounds of formula 1 or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, R6 and X- have one of the meanings as indicated in the specification, to their use as a medicament, to their use in the treatment of a disease selected from among respiratory diseases or complaints and allergic diseases of the airways, to pharmaceutical composition comprising at least one of said compound or a pharmaceutically acceptable salt thereof, as well as to medicament combinations containing one or more of said compounds or a pharmaceutically acceptable salt thereof.

  本发明涉及式1的化合物或其药用盐，其中R1、R2、R3、R5、R6和X-具有规范中指示的含义之一，其用作药物，用于治疗呼吸道疾病或疾病和过敏性疾病，包括至少一种所述化合物或其药用盐的药物组合的制药组合。
• QUINOLONE ANALOGS AND METHODS RELATED THERETO
  申请人：NAGASAWA Johnny Yasuo

  公开号：US20090093455A1

  公开（公告）日：2009-04-09

  The present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.

  本发明提供了新型喹诺酮化合物及其药物组合物，可以抑制细胞增殖和/或诱导细胞凋亡。本发明还提供了制备这种化合物和组合物的方法，以及制备和使用它们的方法。